Arbutus Biopharma (ABUS) EBT (2013 - 2026)
Arbutus Biopharma (ABUS) posted EBT of $169.7 million for Q1 2026, up 3929.84% sequentially from -$4.4 million in Q4 2025, and up 791.81% YoY from $19.0 million in Q1 2025.
Arbutus Biopharma (ABUS) EBT (2013 - 2026) Analysis & Trends
Arbutus Biopharma has reported EBT for 14 years, with the latest figure at $169.7 million in Q1 2026.
- Quarterly EBT rose 791.81% year-over-year to $169.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $160.0 million (up 307.63% YoY) and the FY2025 annual result came in at -$215.5 million, down 208.18% from the prior year.
- EBT grew to $169.7 million in Q1 2026 per ABUS's latest filing, from -$4.4 million in the prior quarter.
- Over five years, EBT peaked at $169.7 million in Q1 2026 and troughed at -$24.5 million in Q1 2025.
- A 5-year average of -$4.3 million and a median of -$17.1 million in 2023 frame the typical range for EBT.
- The sharpest annual moves came in 2023 and 2026: EBT tumbled 44.32% in 2023, then soared 791.81% in 2026.
- Over 5 years, EBT stood at -$21.9 million in 2022, then grew by 11.95% to -$19.3 million in 2023, then surged by 32.8% to -$13.0 million in 2024, then soared by 65.86% to -$4.4 million in 2025, then jumped by 3929.84% to $169.7 million in 2026.
- According to Business Quant data, EBT over the past three periods registered $169.7 million, -$4.4 million, and -$7.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | -5.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.18 Mn |
| Mar 31, 2026 | 169.70 Mn |
| Dec 31, 2025 | -4.43 Mn |
| Sep 30, 2025 | -7.73 Mn |
| Jun 30, 2025 | 2.50 Mn |
| Mar 31, 2025 | -24.53 Mn |
| Dec 31, 2024 | -12.98 Mn |
| Sep 30, 2024 | -19.72 Mn |
| Jun 30, 2024 | -19.85 Mn |
| Mar 31, 2024 | -17.99 Mn |
| Dec 31, 2023 | -19.31 Mn |
| Sep 30, 2023 | -20.10 Mn |
| Jun 30, 2023 | -17.09 Mn |
| Mar 31, 2023 | -16.34 Mn |
| Dec 31, 2022 | -21.93 Mn |
| Sep 30, 2022 | -17.57 Mn |
| Jun 30, 2022 | -14.19 Mn |
| Mar 31, 2022 | -11.32 Mn |
| Dec 31, 2021 | -21.32 Mn |
| Sep 30, 2021 | -19.16 Mn |